discuss everyone. full Thank today, a provide as afternoon, for our fourth the and Thank and quarter XXXX Erica, results. you, good time taking year we business you and to us update join
Mr. financial is drug But provide today Sims, would call our a on Officer. the on on development me to Financial Andrew before remarks my brief two Chief Joining our like focusing update an overview performance, key provides activities, Andrew topics. of our I
Rhenium recurrent RNL, being glioblastoma. clinical from First, progress on And the glioblastoma. target apart clinical on drug also developed indications currently Nanoliposomes, development additional for recurrent an lead of update second, RNL, potential for called our
of lead loaded energy is nanometerliposomes. it those efficient interesting, for technology XXX, is you which that the imaging. made new a to into loaded two and energy because of proprietary rhenium in RNL consisting gamma types, key is killing is releases Now beta therapeutic for reactor energy cancer for drug part RNL, isotopic are our with an who XXX and company, unique
devastating most clear provide is about recur benefit and then glioblastoma. this treatment brain they And a marginal FDA the glioblastoma treat therapy patients. remains recurrent it. for the currently tumors standard in Our U.S., Not is primary same the about for no treatment. only a in care after new been cancer, there lead a indication since annually for few decade the EU. and initial those significant The go RNL of It of is approved disease and recurrent number lethal glioblastoma, all patients in even and which treatments, affects the challenge, will to approved surprisingly, really to it's survival form of essentially the approximately patients common XX,XXX of
unmet So real need. it's true a medical
commonly its used glioblastoma, the really radiation a therapy beam energy times beam radiation as may XX and beam external healthy deliver Compared any against external because whereby tumor treatment tissue radiation delivered with is only potential unwanted to it with through radiation higher used to is tumor, nearby therapy to inherent to dose is therapy, reduced. as RNL the XX as radiation is to by and healthy it Now, external or radiation exposure its possible GBM of RNL, used good radiation other that actually super-high than gets today. doses targeting And despite or better precisely about for it's reach tissue than be up today. efficacy to passes to the capability, tumor of external
tolerability, distribution RNL such patients effectively clinical microscopic treat proprietary Now, nanotechnology that drug and in feasible left determine its both of formed further degree, actually radiation for to including provided the in in cohort November trial XXXX called nanotechnology, we better funded other the stays glioblastoma, no industry tumor be patients we X,XXX funded previously fold cancer up as for us real-time can we've the XXXX. those that that and efficacy mentioned NIH, and granted is track of preclinical actually the an serious development guide first This in neuro-oncology FDA into and data concomitantly to was a adverse seen successfully we winding trial our significant and fields tissue neuro-oncology, assess Phase there's fast scientific In National may In ongoing advance toxicity clinical dose is cancers, designations and healthy maximum thus of steps successfully dose bulk RNL therapy. the of dose to are is in the found of drug. brain of neurosurgery, and the volume detail both SAE, brain boards advisory and But as to doctors and the will in treatment marrow program on our to in for adjacent energy times markedly gamma ReSPECT were produced beam that track or the on the external ReSPECT the time, radiation company one from in the XXXX, for of showed Institute. during our the brief to often advise that glioma radiation with disease to the or events supply Plus systemic, degree XX the for dose assist and the intratumoral penumbra Also, from can and I through order is design the the in a control XXX and to dose X patients sorry, view, society administration for ReSPECT orphan between for XX or data of the on exposure were in Phase experts potential plan XX plan, RNL. clinical safety, distribution up the trial was radiation. by to These tissue. on RNL be update by observed, RNL Through the the to to can regulatory very the the cohort. cohorts reason X deliver the RNL more ability brain significant earlier far, about interim and meeting, radiation At that's the development. the compared doses In outside progressive ablation of our that a fifth versatile in optimization low, data the forward EBRT the help and ReSPECT, well the malignant standards external recurrent difference despite XXXX our and two. allow beam remain clinical absorbed of anticipation absorbed next standard radiation and last on was administered of treatment by annual the up trial in RNL successfully RNL RNL the development, and `website. no tumor interim and the efforts bringing boards increased with forward. develop manufacturing visualized limiting program XXXX, current X/X higher a Cancer year, glioblastoma, leaders radiation, in The in chains tolerated available, and
volume, with show escalation duration and treated six patients the of dose survivors dosage that efficacy trial se, seen mean the is delivery two long-term months third designed XX%, enrollment we currently can Anderson we increasing per but growing additional X.X is a completed not the ReSPECT than the than more required clinical you patients patients In XX.X six the with subjects Although have the trial, the enrollment Cancer cohort parameters. to planned coverage of greater respectively, three in site to at we drug three greater drug interim, Houston. of both radiation And an and XX which months, with survival cohort in ReSPECT volume at again. months, and the additionally, have one part and and a of RNL tell aggressive Center expanded tumor I in We've median still once and alive. six dose trial
ReSPECT trial. thus Phase we of planning So now Corporate or for complete about website. in GBM can as trial GBM summary, strength far, now, enrollment treated the year, the Phase The actually depending latest in year-end The XXXX, the FDA of patient to update X year patients in complete would ready pivotal be by data such be activities and is well feedback. early in with a course, CMC X potentially February found BIO that a from recurrent on CEO XXXX, on in this critical XX as have our which is our the presentation, been
Now, switching clinical trials. move is glioblastoma A forward recurrent clinical gears XXXX, RNL. beyond and to programs indications regarding development us into in additional priority for for additional
approach patients number for Although near-term potential term very leptomeningeal focus brain that's XXX,XXX as used rarer, additional we clear prognosis. care metastases delivery. promising direct difficult approach enhanced do CNS efforts we the to about mirror in pediatric standard though preclinical two despite The cancer, affects targeting rapidly brain U.S., more them. cancers, equally indications, of in for in, brain these and treatment our there on indications we carries metastasis a leptomeningeal intend what pediatric cancers. also to All to Pediatric is two no glioblastoma, cancer would have die our adults an of leptomeningeal patients and carcinomatosis, modern with And and data provide which treat poor are using anticipated much both care. the conduction
Therefore, lining be And into there. thus spinal these fluid, to However, preclinical seemed look is disease studies a LN indwelling CSF of injected approach, the the an cerebrospinal patients. fluid delivery commonly would go circulate space, would placed or if and direct to typically of which that freely is nanoliposome which far in the reservoir, promising. to LN
fill may patients, XXXX, is that currently FDA part understand in into these pre-IND the if for of preclinical hopefully XXXX, to year-end the as move data, goal have indications possible, as those by as gaps rapidly and needed in with both meetings Our early the have we any then possible.
drug as we efficiency for program previously intend and philosophy note Texas funding expenditures, and capital stated of for help we've final maximum to to our with possible, a development a CPRIT activities, its dilution through of development mentioned consistent other apply our on minimal support whenever shareholder As calls. State in striving
So the Andrew? the call to let review turn me a that, Andrew for over financial of now with results.
